Introduction
Human newborns suffer a high frequency of microbial infection resulting in morbidity and mortality 1, 2 . Neonatal immunization is desirable because: a) newborns are susceptible to multiple bacterial and viral pathogens, b) strategies involving immunization of the mother pose substantial logistical and medico-legal challenges, and c) birth represents a reliable point of health care contact and therefore newborn immunization results in a substantially higher rate of vaccination coverage 3 . Unfortunately, many vaccines are ineffective in newborns, thereby frustrating immunization efforts in this susceptible population 4 . Thus, there is an unmet medical need to develop improved vaccination approaches to prevent neonatal infection.
The poor responses of newborns to multiple vaccines have been traditionally ascribed to "immaturity" of the neonatal immune system. A more nuanced view is emerging as it is increasingly recognized that expression of T helper cell type I (Th1)-type immunity is impaired at birth, and there is a strong T helper cell type II (Th2)-bias to many aspects of the neonatal immune response 5 . Th2 polarization of the neonatal immune response is thought to protect the fetus from potentially harmful inflammatory reactions that could trigger premature delivery and its attendant complications 6, 7 . However, such Th2 polarization biases against the Th1-type immune responses required for effective cell mediated immunity and for effective immune responses to some vaccines. Some complex stimuli such as bacillus Calmette-Guerin (BCG) effectively induce Th1-type immune responses in neonates 8 , but the molecular rules governing why a particular stimulus does or does not stimulate neonatal Th1 immunity are not well understood. Efforts to prevent and treat neonatal infections are therefore limited by incomplete understanding of the neonatal immune response, and, in particular, mechanisms by which the neonatal adaptive immune system may be instructed to generate Th1-type responses.
For personal use only. on May 9, 2017 . by guest www.bloodjournal.org From Generation of Th1-type immune responses, including memory responses to many vaccines, is dependent upon appropriate activation of antigen-presenting cells (APCs), including macrophages and dendritic cells (DCs) that function at the interface of innate and adaptive immunity 9 . APCs take up foreign antigens, digest them, and display antigen fragments on the cell surface in the context of MHC molecules, thereby presenting them to antigenspecific T cells. Among the APCs, DCs are the most efficient activators of naïve T cells both in vitro and in vivo. In particular, myeloid DCs (mDCs) capture antigens in the periphery, then migrate to the lymphoid organs to initiate immunity 10 and are mobilized to sites of viral entry during viral infection 11 . Effective APC-induced activation of T cells requires the expression by APC of co-stimulatory molecules, including: 1) IL-12, a soluble heterodimer (p40-p35) that activates antigen-specific CD4 lymphocytes 12 , and 2) CD40, a cell surface receptor that binds CD40 ligand on T cells, resulting in activation of kinase cascades culminating in NF-κB activation and consequent regulation of DC activity as well as T cell priming and differentiation 13, 14 . In general, the functional responses of neonatal APCs, including synthesis of IL-12 15 and upregulation of CD40 16 are limited.
APCs express TLRs that act as homo-or hetero-dimers to recognize and respond to a wide variety of microbial components 17 . TLR-mediated activation of APCs triggers expression of co-stimulatory molecules necessary for effective T cell activation and subsequent memory responses 18 . Of note, TLR7 and TLR8 are members of a genetically-and structurally-related subfamily of TLRs 19, 20 that have evolved to recognize unmodified ribonucleic acids 21 .
Guanosine-and uridine-rich single stranded RNAs (ssRNAs) derived from HIV-1 activate murine cells via TLR7 and human cells via TLR8 22 . In addition, small synthetic compounds known as imidazoquinolines, including imiquimod and R-848, activate cells of galliform 
Materials and methods

Blood
Peripheral blood was collected from healthy adult volunteers (N = 33; mean age 27 years) and newborn cord blood (N = 33; mean gestational age 38.4 weeks) collected immediately after Cesarean section delivery (epidural anesthesia) of the placenta. Births at which antibiotics were administered during labor and/or delivery, and births to HIVpositive mothers were excluded. Approval was obtained from the Children's Hospital Boston and Brigham and Women's Hospital institutional review boards for these studies. 
Isolation of mononuclear cells and monocytes
Heparinized blood was layered onto Ficoll-Hypaque gradients (Sigma-Aldrich, St. Louis, MO), the peripheral blood mononuclear cell (PBMC) layer collected, and subjected to hypotonic lysis to remove red blood cells as previously described 32 . Monocytes were isolated from PBMC by negative selection using a cocktail of biotin-conjugated mAb's directed against CD3, CD7, CD16, CD19, CD56, CD123, and Glycophorin A as well as anti-biotin-conjugated magnetic microbeads according to the manufacturer's instructions (Monocyte Isolation Kit II; Miltenyi Biotec, Auburn, CA). This procedure routinely yielded monocytes preparations with purity of ~90% as assessed by measuring CD14
staining by flow cytometry as previously described 32 .
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TLR agonists
TLR agonists used in this study are listed in Table 1 containing a GU-rich sequence) both commercially prepared as cationic lipid complexes to facilitate cellular uptake (InvivoGen). Specificity of imidazoquinolone congeners, including the novel TLR7 agonist 3M-013, was determined using HEK293 cells and an NF-κB-luciferase reporter (BD Clontech) as previously described 26 .
For study of TLR-induced responses in suspension, cells (PBMCs at 10 6 /ml or monocytes at 3 x 10 6 /ml) were cultured in 100% fresh autologous serum and stimulated with end-over-end rotation at 37 o C. For study of TLR-induced IL-12 production, monocytes were prepared by allowing PBMCs to adhere onto 24-well plates for 1 h at 37 o C/5% CO 2 . Non-adherent cells were removed with two washes of Minimal Essential Medium (MEM; Gibco BRL) and adherent monocytes incubated in the presence of 10% autologous serum in MEM for 48 h.
Cytokine measurement
Concentrations of TNF-α and IL-12 were determined by dilution of samples with five-or two-volumes, respectively, of ice-cold RPMI medium (Gibco BRL) and centrifugation at 
Identification of mDCs and measurement of CD40 expression
To assess the upregulation of CD40 expression on mDCs, whole blood was anti- 
Measurement of TLR8 expression
For measurement of TLR8 expression by flow cytometry, whole blood was processed as for CD40 measurement, using markers for monocytes and for mDCs as described above.
APCs were stained for TLR8 (PE; Imgenex, San Diego, CA) after permeabilizing with Perm2 Buffer (BD BioSciences). A TLR8 Expression Index was calculated within cell populations as a product of (median fluorescent intensity of mDC's) x (% of mDCs positive for TLR8).
Phosphorylation of p38 MAPK
Following incubation of heparinized whole blood with TLR agonists for 10 minutes at 
IκB-α Western Blot
Neonatal and adult monocytes were cultured in 100% fresh autologous serum (2. (National Institutes of Health, USA). After creating a profile of image density for the blot area corresponding to the protein size of interest, IκB-α levels were determined by measuring the area under each band peak. As a loading control, actin was stained using an anti-human actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Statistical analysis
Data were analyzed using Prism 4 for MacIntosh v. 4.0a (GraphPad Software Inc.; San Diego, CA). Data in figures represent means + SEM. The Mann-Whitney test was used for statistical analysis for all paired comparisons and the Spearman test was used to determine the significance of the correlation of p38 phosphorylation with TNF-α production. P values less than 0.05 were considered significant.
For
Results
TLR8 agonists preferentially induce robust TNF-α production in both neonatal and adult blood
We have previously shown that R-848 (TLR7/8) effectively induced TNF-α production from neonatal monocytes whereas imiquimod (TLR7) did not 32 , raising the possibility that agents that signal via TLR8 possess unique efficacy in inducing TNF-α from neonatal monocytes. To assess the specificity of TLR agonists in neonatal TNF-α induction, we compared the ability of a panel of TLR agonists, including those that activate via TLR7, TLR 7/8, or TLR8 only to induce TNF-α production in citrated peripheral adult blood or neonatal cord blood (Fig. 1) . Agonists of TLR2/6 (MALP) and of TLR7 (3M-013 and imiquimod) induced limited amounts of TNF-α (< 10,000 pg/mL).
In contrast, 3M-003 and R-848, both agonists of TLR 7 and 8, induced substantial TNF-α production reaching 20,000-80,000 pg/mL. Similarly, agonists that signal via TLR8 alone, including 3M-002, ssRNA40 and ssRNA poly U, induced substantial TNF-α production that was equivalent in neonatal and adult blood. These results suggest that signaling via TLR8 (with or without TLR7) results in generally greater TNF-α induction and a relatively greater activation of neonatal cells than activation of other TLRs.
A similar pattern of neonatal and adult TNF-α production, with relatively high TLR8-induced TNF-α production, was noted using heparin (instead of citrate) as anticoagulant, indicating that the pattern is independent of the means of anti-coagulation (not shown).
TLR8 agonists fully activate neonatal and adult mononuclear cells
To determine whether the preferential efficacy of TLR8 agonists noted in whole blood extended to assays with isolated mononuclear cells, we compared the ability of TLR 7, TLR 7/8 and TLR8 agonists to activate neonatal and adult mononuclear cells in 100% autologous serum (Fig. 2) . Whereas the TLR7 agonist 3M-013 induced lower TNF-α in newborn than adult cells, 3M-003 (TLR7/8) and 3M-002 (TLR8) induced robust TNF-α in both newborn and adult PBMCs. In addition to confirming the overall pattern of TLR responses noted in whole blood, these data also indicate that the pattern of preferential responsiveness of neonatal PBMCs to TLR8 agonists is independent of the presence of other blood cells (e.g., red blood cells and neutrophils) and is manifest in serum as well as plasma.
TLR8 agonists effectively induce IL-12 synthesis by adherent neonatal and adult monocytes
IL-12 is a heterodimeric cytokine that is crucial for driving Th1-type responses and cell-mediated immunity 12 . To determine whether the efficacy of TLR8 agonists towards neonatal APC extends to induction of IL-12, we compared the ability of MALP (TLR2/6) and LPS (TLR4) with that of TLR7, TLR 7/8, and TLR8 agonists to induce IL-12 p40/70 production from adherent monocytes derived from neonates and adults (Fig.   3 ). MALP failed to induce detectable neonatal IL-12 synthesis and LPS preferentially induced IL-12 in adult cells. Similarly, TLR7 agonists (3M-013 and imiquimod) induced modest IL-12 production (< 350 pg/mL) in adults and were even less active in newborns.
In marked contrast, agonists of TLR 7/8 (3M-003 and R-848) as well as TLR8 (3M-002,
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TLR8 agonists preferentially induce CD40 expression by neonatal and adult mDCs
The ability of TLR8 agonists to effectively induce production of the Th1-polarizing cytokines TNF-α and IL-12 from neonatal mononuclear cells raises the possibility that these agents may have unique efficacy in activating neonatal APC. To explore the ability of TLR8 agonists to activate neonatal APC, we measured the ability of TLR8 agonists to induce up-regulation of the surface co-stimulatory molecule CD40 on neonatal and adult mDCs using flow cytometry (Fig. 4) . Agonists of TLR2/6 (MALP) and TLR4 (LPS) induced modest upregulation of CD40 on neonatal mDCs (~5 -35% CD40 positive). Similarly, the TLR7 agonists imiquimod and 3M-013 induced < 35% CD40 positivity in neonatal (or adult) cells. In contrast, TLR8 agonists, including the TLR 7/8 agonists R-848 and 3M-003 as well as the pure TLR8 agonists 3M-002 and ssRNA40 effectively induced >50 -80% CD40 positivity in neonatal mDCs.
Neonatal monocytes and myeloid dendritic cells express equivalent amounts of TLR8 protein as do their adult counterparts
To begin assessing the mechanism by which TLR8 agonists maintain full activity towards neonatal APCs, we characterized basal expression of TLR8 protein in neonatal and adult APCs. We have previously reported that neonatal monocytes exhibit normal basal expression of TLR8 mRNA 32 , but to date there is no published information
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Comparison of TLR8 staining by percent positivity, median fluorescence intensity (MFI), or Expression Index (percent positive X MFI) demonstrated equivalent TLR8 protein expression in neonatal and adult monocytes (Fig. 5E ) as well as in neonatal and adult mDCs (Fig. 5F ). These data indicate that, on a cellular basis, neonatal monocytes and mDCs express similar amounts of TLR8 protein as their adult counterparts.
TLR8 agonists effectively and preferentially induce phosphorylation of p38
MAPK in neonatal and adult monocytes
The preferential response of neonatal APCs to TLR8 agonists raises the question of the mechanism by which TLR8 agonists are so efficacious at activating Th1-polarizing responses. To begin assessing this issue, we employed flow cytometry to measure the ability of TLR agonists to induce phosphorylation of p38 MAPK in neonatal and adult monocytes (Fig. 6) . Whereas 3M-013 and imiquimod induced little or no detectable phosphorylation of p38 MAPK (see representative experiment, Fig. 6A ), the TLR7/8 agonists 3M-003 and R-848 as well as the pure TLR8 agonist 3M-002 induced robust p38 phosphorylation in both neonatal and adult monocytes (see representative experiment Fig. 6B ). Composite analysis of such data revealed that TLR8 and TLR7/8 agonists induced significantly more phosphorylation of p38 than did TLR7 agonists (Fig. 6C ).
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Spearman analysis indicated that TLR-induced p38 phosphorylation and TLR-induced TNF-α production were significantly correlated (adults: r = 0.7973, r 2 = 0.6357, P = 0.0029; newborns: r = 0.8322, r 2 = 0.6926; P = 0.0013).
Preferential degradation of IκB-α by a TLR8 agonist
To further characterize the mechanism of activation of neonatal and adult monocytes by TLR8 agonists, we compared TLR7-and TLR8-mediated disappearance of IκB-α. Neonatal and adult monocytes were stimulated with the pure TLR7 agonist 3M-013 or the pure TLR8 agonist 3M-002 for 10, 30 or 60 min prior to assay for IκB-α by
Western blotting (Fig. 7) . As shown in a representative experiment, newborn (Fig. 7A) and adult ( (Fig. 7C &D) . TLR7 stimulation induced a transient and modest (~ 50%) reduction in IκB-α levels that for neonatal cells lost significance by 60 min (Fig. 7C) . In contrast, TLR8 stimulation induced a profound (~ 90%) reduction in IκB-α levels that remained significant in neonates at 60 minutes (Fig.   7D ). These results suggest that activation of TLR8 results in more profound and prolonged degradation of IκB-α that may contribute to the efficacy of TLR8 agonists in activating neonatal and adult APCs.
Discussion
Multiple studies have documented impaired neonatal Th1-type immune responses to a variety of stimuli [32] [33] [34] [35] [36] . Building on our prior study that indicated that a TLR 7/8 agonist (R-848) had preserved TNF-α-inducing activity in neonatal monocytes 32 , we have assessed the ability of TLR8 agonists to activate neonatal APCs. We have discovered that agents that activate cells via TLR8 have a unique ability to induce production of Th1-responses in neonatal APC, revealing a unique preservation of the TLR8-mediated activation pathway in human newborns.
In contrast to agonists of TLR2/6, TLR4 or TLR7 (only), agonists of TLR8 (or TLR 7/8) effectively induced production of the pro-inflammatory and Th1-polarizing cytokine TNF-α from mononuclear cells in a range of relatively physiologic assay formats, including whole blood ( Fig. 1) and PBMCs cultured in fresh autologous serum (Fig. 2) . TLR8 agonists also effectively induced production of IL-12, a cytokine that enhances cell-mediated immunity 12 , from adherent monocytes cultured in fresh autologous serum (Fig. 3) . In addition, TLR8 agonists preferentially induced expression of the co-stimulatory molecule CD40 on neonatal mDCs (Fig. 4) , a population of mononuclear cells known to express TLR8 26 and that play important roles in antigen presentation 37 . We demonstrate that on a cellular basis, neonatal monocytes and mDCs express TLR8 protein to a similar extent as adult monocytes and mDCs (Fig. 5) .
The overall efficacy of TLR8 agonists in activating neonatal APC generally correlated with their higher efficacy, in comparison to agonists of other TLRs, in inducing Th1 responses from adult mononuclear cells as well. Such a pattern suggests that the efficacy of TLR8 agonists in newborns may reflect their greater stimulatory
For personal use only. on May 9, 2017. by guest www.bloodjournal.org From activity. Indeed, the efficacy of TLR8 agonists in activating neonatal APCs correlated with their ability to effectively induce phosphorylation of p38 MAPK (Fig. 6 ) as well as their ability to induce prolonged degradation of IκB-α (Fig. 7) . In aggregate, these results suggest that the unique potency of TLR8 agonists relates to the ability of the TLR8 pathway to strongly induce TLR-mediated intracellular signaling via the p38 MAPK and NF-κB pathways that are known to trigger expression of co-stimulatory molecules including TNF-α 38,39 , IL-12 40 and CD40 41 .
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